Interestingly, in the follow-up phase, BHR and signs of inflammation in carriers of GSTP1 slow activity genotype were present despite ongoing treatment with asthma medication, suggesting that chronic inflammation had developed in their bronchi more often than in subjects with unaltered activity associated GSTP1 genotypes. This evidence concerns the gene GSTP1 and asthma.